Market Research

Acute Intermittent Porphyria Market (Diagnosis: Blood test, Urine Test, DNA Test, and Serum Test; Treatment: Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 140 Pages Transparency Market Research Pvt. Ltd. April, 2024 TNPR18827819
Best Price Guarantee
Price from $5,795
Length 140 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date April, 2024
SKU TNPR18827819

Acute Intermittent Porphyria Market (Diagnosis: Blood test, Urine Test, DNA Test, and Serum Test; Treatment: Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


Acute Intermittent Porphyria Market – Scope of Report

TMR’s report on the global acute intermittent porphyria market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global acute intermittent porphyria market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute intermittent porphyria market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the acute intermittent porphyria market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute intermittent porphyria market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global acute intermittent porphyria market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute intermittent porphyria market.

The report delves into the competitive landscape of the global acute intermittent porphyria market. Key players operating in the global acute intermittent porphyria market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global acute intermittent porphyria market profiled in this report.

Key Questions Answered in Global acute intermittent porphyria Market Report
  • What is the sales/revenue generated by acute intermittent porphyria across all regions during the forecast period?
  • What are the opportunities in the global acute intermittent porphyria market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Acute Intermittent Porphyria Market – Research Objectives and Research Approach

The comprehensive report on the global acute intermittent porphyria market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute intermittent porphyria market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute intermittent porphyria market.


1. Preface
  1.1. Market Definition and Scope
  1.2. Market Segmentation
  1.3. Key Research Objectives
  1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Acute Intermittent Porphyria Market
4. Market Overview
  4.1. Introduction
  4.1.1. Product Definition
  4.1.2. Industry Evolution/Developments
  4.2. Overview
  4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunities
  4.4. Acute Intermittent Porphyria Market Analysis and Forecast, 2020-2034
5. Key Insights
  5.1. Pipeline Analysis
  5.2. Key Product /Brand Analysis
  5.3. Key Mergers & Acquisitions
  5.4. COVID-19 Pandemic Impact on Industry
6. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Diagnosis
  6.1. Introduction & Definition
  6.2. Key Findings/Developments
  6.3. Market Value Forecast, by Diagnosis, 2020-2034
  6.3.1. Blood Test
  6.3.2. Urine Test
  6.3.3. DNA Test
  6.3.4. Serum Test
  6.4. Market Attractiveness Analysis, by Diagnosis
7. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Treatment
  7.1. Introduction & Definition
  7.2. Key Findings/Developments
  7.3. Market Value Forecast, by Treatment, 2020-2034
  7.3.1. Gonadotropin-Releasing Hormone Analogues
  7.3.2. Prophylactic Hematin Infusions
  7.4. Market Attractiveness Analysis, by Treatment
8. Global Acute Intermittent Porphyria Market Analysis and Forecast, by End-user
  8.1. Introduction & Definition
  8.2. Key Findings/Developments
  8.3. Market Value Forecast, by End-user, 2020-2034
  8.3.1. Hospitals
  8.3.2. Clinics
  8.3.3. Research Centers
  8.4. Market Attractiveness Analysis, by End-user
9. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Region
  9.1. Key Findings
  9.2. Market Value Forecast, by Region, 2020-2034
  9.2.1. North America
  9.2.2. Europe
  9.2.3. Asia Pacific
  9.2.4. Latin America
  9.2.5. Middle East & Africa
  9.3. Market Attractiveness Analysis, by Region
10. North America Acute Intermittent Porphyria Market Analysis and Forecast
  10.1. Introduction
  10.2. Key Findings
  10.3. Market Value Forecast, by Diagnosis, 2020-2034
  10.3.1. Blood Test
  10.3.2. Urine Test
  10.3.3. DNA Test
  10.3.4. Serum Test
  10.4. Market Value Forecast, by Treatment, 2020-2034
  10.4.1. Gonadotropin-Releasing Hormone Analogues
  10.4.2. Prophylactic Hematin Infusions
  10.5. Market Value Forecast, by End-user, 2020-2034
  10.5.1. Hospitals
  10.5.2. Clinics
  10.5.3. Research Centers
  10.6. Market Value Forecast, by Country, 2020-2034
  10.6.1. U.S.
  10.6.2. Canada
  10.7. Market Attractiveness Analysis
  10.7.1. By Diagnosis
  10.7.2. By Treatment
  10.7.3. By End-user
  10.7.4. By Country
11. Europe Acute Intermittent Porphyria Market Analysis and Forecast
  11.1. Introduction
  11.2. Key Findings
  11.3. Market Value Forecast, by Diagnosis, 2020-2034
  11.3.1. Blood Test
  11.3.2. Urine Test
  11.3.3. DNA Test
  11.3.4. Serum Test
  11.4. Market Value Forecast, by Treatment, 2020-2034
  11.4.1. Gonadotropin-Releasing Hormone Analogues
  11.4.2. Prophylactic Hematin Infusions
  11.5. Market Value Forecast, by End-user, 2020-2034
  11.5.1. Hospitals
  11.5.2. Clinics
  11.5.3. Research Centers
  11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  11.6.1. Germany
  11.6.2. U.K.
  11.6.3. France
  11.6.4. Italy
  11.6.5. Spain
  11.6.6. Rest of Europe
  11.7. Market Attractiveness Analysis
  11.7.1. By Diagnosis
  11.7.2. By Treatment
  11.7.3. By End-user
  11.7.4. By Country/Sub-region
12. Asia Pacific Acute Intermittent Porphyria Market Analysis and Forecast
  12.1. Introduction
  12.2. Key Findings
  12.3. Market Value Forecast, by Diagnosis, 2020-2034
  12.3.1. Blood Test
  12.3.2. Urine Test
  12.3.3. DNA Test
  12.3.4. Serum Test
  12.4. Market Value Forecast, by Treatment, 2020-2034
  12.4.1. Gonadotropin-Releasing Hormone Analogues
  12.4.2. Prophylactic Hematin Infusions
  12.5. Market Value Forecast, by End-user, 2020-2034
  12.5.1. Hospitals
  12.5.2. Clinics
  12.5.3. Research Centers
  12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  12.6.1. China
  12.6.2. Japan
  12.6.3. India
  12.6.4. Australia & New Zealand
  12.6.5. Rest of Asia Pacific
  12.7. Market Attractiveness Analysis
  12.7.1. By Diagnosis
  12.7.2. By Treatment
  12.7.3. By End-user
  12.7.4. By Country/Sub-region
13. Latin America Acute Intermittent Porphyria Market Analysis and Forecast
  13.1. Introduction
  13.2. Key Findings
  13.3. Market Value Forecast, by Diagnosis, 2020-2034
  13.3.1. Blood Test
  13.3.2. Urine Test
  13.3.3. DNA Test
  13.3.4. Serum Test
  13.4. Market Value Forecast, by Treatment, 2020-2034
  13.4.1. Gonadotropin-Releasing Hormone Analogues
  13.4.2. Prophylactic Hematin Infusions
  13.5. Market Value Forecast, by End-user, 2020-2034
  13.5.1. Hospitals
  13.5.2. Clinics
  13.5.3. Research Centers
  13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  13.6.1. Brazil
  13.6.2. Mexico
  13.6.3. Rest of Latin America
  13.7. Market Attractiveness Analysis
  13.7.1. By Diagnosis
  13.7.2. By Treatment
  13.7.3. By End-user
  13.7.4. By Country/Sub-region
14. Middle East & Africa Acute Intermittent Porphyria Market Analysis and Forecast
  14.1. Introduction
  14.2. Key Findings
  14.3. Market Value Forecast, by Diagnosis, 2020-2034
  14.3.1. Blood Test
  14.3.2. Urine Test
  14.3.3. DNA Test
  14.3.4. Serum Test
  14.4. Market Value Forecast, by Treatment, 2020-2034
  14.4.1. Gonadotropin-Releasing Hormone Analogues
  14.4.2. Prophylactic Hematin Infusions
  14.5. Market Value Forecast, by End-user, 2020-2034
  14.5.1. Hospitals
  14.5.2. Clinics
  14.5.3. Research Centers
  14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  14.6.1. GCC Countries
  14.6.2. South Africa
  14.6.3. Rest of Middle East & Africa
  14.7. Market Attractiveness Analysis
  14.7.1. By Diagnosis
  14.7.2. By Treatment
  14.7.3. By End-user
  14.7.4. By Country/Sub-region
15. Competition Landscape
  15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  15.2. Market Share Analysis, by Company (2023)
  15.3. Company Profiles
  15.3.1. Alnylam Pharmaceuticals, Inc.
  15.3.1.1. Company Overview
  15.3.1.2. Product Portfolio
  15.3.1.3. SWOT Analysis
  15.3.1.4. Financial Overview
  15.3.1.5. Strategic Overview
  15.3.2. Clinuvel Pharmaceuticals Ltd.
  15.3.2.1. Company Overview
  15.3.2.2. Product Portfolio
  15.3.2.3. SWOT Analysis
  15.3.2.4. Financial Overview
  15.3.2.5. Strategic Overview
  15.3.3. BioMarin Pharmaceutical Inc.
  15.3.3.1. Company Overview
  15.3.3.2. Product Portfolio
  15.3.3.3. SWOT Analysis
  15.3.3.4. Financial Overview
  15.3.3.5. Strategic Overview
  15.3.4. Recordati
  15.3.4.1. Company Overview
  15.3.4.2. Product Portfolio
  15.3.4.3. SWOT Analysis
  15.3.4.4. Financial Overview
  15.3.4.5. Strategic Overview
  15.3.5. Quest Diagnostics
  15.3.5.1. Company Overview
  15.3.5.2. Product Portfolio
  15.3.5.3. SWOT Analysis
  15.3.5.4. Financial Overview
  15.3.5.5. Strategic Overview
  15.3.6. Invitae Corp.
  15.3.6.1. Company Overview
  15.3.6.2. Product Portfolio
  15.3.6.3. SWOT Analysis
  15.3.6.4. Financial Overview
  15.3.6.5. Strategic Overview
  15.3.7. Laboratory Corporation of America Holdings (Labcorp)
  15.3.7.1. Company Overview
  15.3.7.2. Product Portfolio
  15.3.7.3. SWOT Analysis
  15.3.7.4. Financial Overview
  15.3.7.5. Strategic Overview
  15.3.8. ARUP Laboratories
  15.3.8.1. Company Overview
  15.3.8.2. Product Portfolio
  15.3.8.3. SWOT Analysis
  15.3.8.4. Financial Overview
  15.3.8.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings